SEC Form 4 · accession 0000899243-17-006500
BIODELIVERY SCIENCES INTERNATIONAL INC · BDSI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Niraj Vasisht
Officer — SVP & Chief Technology Officer
Period of report
Feb 22, 2017
Accepted (ET)
Mar 3, 2017 · 7:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001103021
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 22, 2017 | M | 24,980 | $0.00 | A | 196,802 | D | |
| Common StockF3 | Feb 22, 2017 | S | 9,500 | $2.01 | D | 187,302 | D | |
| Common StockF4 | Feb 23, 2017 | M | 66,667 | $0.00 | A | 253,969 | D | |
| Common StockF5 | Feb 23, 2017 | S | 23,500 | $1.95 | D | 230,469 | D | |
| Common StockF6 | Mar 1, 2017 | M | 50,000 | $0.00 | A | 280,469 | D | |
| Common StockF7 | Mar 1, 2017 | S | 9,000 | $2.03 | D | 271,469 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units | $0.00 | Feb 22, 2017 | M | 24,980 | A | Feb 22, 2017 | Feb 22, 2017 | Common Stock | 24,980 | 0 | D |
| Restricted Stock Units | $0.00 | Feb 23, 2017 | M | 66,667 | A | Feb 23, 2017 | Feb 23, 2018 | Common Stock | 66,667 | 66,666 | D |
| Restricted Stock Units | $0.00 | Mar 1, 2017 | M | 50,000 | A | Mar 1, 2017 | Mar 1, 2019 | Common Stock | 50,000 | 100,000 | D |
Explanation of responses
- F1The shares of common stock were acquired by the Reporting Person as a result of the vesting of the remaining RSUs that had been granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan").
- F2The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of the RSUs.
- F3On February 22, 2017, the Reporting Person sold an aggregate of 9,500 shares of the Issuer's Common Stock at a weighted average price of $2.01 per share. The highest sale price for the Common Stock was $2.06 per share and the lowest sale price was $1.96 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. The remainder of the RSUs under this grant will vest on February 23, 2018.
- F5On February 23, 2017, the Reporting Person sold an aggregate of 23,500 shares of the Issuer's Common Stock at a weighted average price of $1.95 per share. The highest sale price for the Common Stock was $2.05 per share and the lowest sale price was $1.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. The remainder of the RSUs under this grant will vest in equal installments on March 1, 2018 and March 1, 2019.
- F7On March 1, 2017, the Reporting Person sold an aggregate of 9,000 shares of the Issuer's Common Stock at a weighted average price of $2.03 per share. The highest sale price for the Common Stock was $2.05 per share and the lowest sale price was $2.00 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.